Benzodiazepine use and risk of incident dementia or cognitive decline: prospective population based study
The dementia evidence on benzodiazepines points both ways - how do you weigh it for someone my age, and does it change how long I should stay on this?
Well-supported by good-quality research. how we score evidence
Caveat on this rating: Slightly elevated risk appeared at low but not high exposure - a pattern inconsistent with causation - yet the finding conflicts with the Billioti de Gage 2014 case-control study; the question remains unsettled.
Following 3,434 adults aged 65+ for a mean of 7.3 years, the highest cumulative benzodiazepine users showed no increased dementia risk (hazard ratio 1.07, 95% CI 0.82 to 1.39), a result that argues against a causal benzodiazepine-dementia link.
Worth asking
The dementia evidence on benzodiazepines points both ways - how do you weigh it for someone my age, and does it change how long I should stay on this?
What it is FDA approved for
Read off the label. Trial duration and approval year are shown only where they were recorded — never inferred.
- Generalized anxiety disorder (acute treatment)
- Panic disorder, with or without agoraphobia
Source
Benzodiazepine use and risk of incident dementia or cognitive decline: prospective population based study — Gray SL, et al. (2016)
Top-tier peer-reviewed journal
Read the source: https://doi.org/10.1136/bmj.i90
DOI: 10.1136/bmj.i90
How this was scored
- Study design
- Cohort study
- Funding
- Independently funded
- Published in
- Top-tier peer-reviewed journal
- Sample size
- 3,434
- Preregistered
- No
- Conflicts disclosed
- Yes
- Independent of proponent
- Yes
- Retracted
- No
Read the full scoring rubric, including what it can't tell you.
Published August 19, 2026.
Questions
How strong is the evidence behind this?
Resolv rates this source "strong evidence". Well-supported by good-quality research. It scores 77 out of 100 on our published rubric. One caveat travels with that badge: Slightly elevated risk appeared at low but not high exposure - a pattern inconsistent with causation - yet the finding conflicts with the Billioti de Gage 2014 case-control study; the question remains unsettled. The score is calculated from recorded facts about the source — study design, funding, publication venue, sample size, preregistration — not typed in by an editor.
What is the source for this?
Benzodiazepine use and risk of incident dementia or cognitive decline: prospective population based study — Gray SL, et al. (2016). Published in: Top-tier peer-reviewed journal. DOI: 10.1136/bmj.i90. The full source is linked on this page so you can read it yourself.
Who paid for this research, and does that matter?
Study design: Cohort study. Funding: Independently funded. The researchers were independent of whoever benefits from the result. Industry sponsorship is one of the most reliably measured biases in medicine, which is why funding carries real weight in the score rather than sitting in a footnote.
Is alprazolam (Xanax), xanax FDA approved?
Yes — FDA approved for Generalized anxiety disorder (acute treatment), Panic disorder, with or without agoraphobia. Approval is for a specific indication, not for everything the drug is prescribed for.
Is this medical advice?
This is information to bring to your prescriber, not medical advice and not a reason to change anything on your own. Nothing here is an instruction to stop or reduce a medication. If you are in crisis, call or text 988.
This is information to bring to your prescriber, not medical advice and not a reason to change anything on your own. Nothing here is an instruction to stop or reduce a medication. If you are in crisis, call or text 988.